BAP1 and nonpapillary renal cell carcinoma: While mutations in BAP1 and PBRM1 have been shown to be associated with poor cancer-specific survival [1, 4, 5], the frequency of these mutations (and their clinical relevance) in metastatic ccRCC tumors is unknown.